Skip to main content

Drugs

Ausgabe 7/2022

Inhalt (10 Artikel)

Review Article

PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer

Ronan Flippot, Anna Patrikidou, Mihaela Aldea, Emeline Colomba, Pernelle Lavaud, Laurence Albigès, Natacha Naoun, Pierre Blanchard, Mario Terlizzi, Camilo Garcia, Alice Bernard-Tessier, Alina Fuerea, Mario Di Palma, Bernard Escudier, Yohann Loriot, Giulia Baciarello, Karim Fizazi

Review Article

Lupus Nephritis: Improving Treatment Options

Myrto Kostopoulou, Sofia Pitsigavdaki, George Bertsias

Review Article

New Drug Delivery Systems Developed for Brain Targeting

Shruti U. Rawal, Bhoomika M. Patel, Mayur M. Patel

Systematic Review

Adverse Events Associated with Immune Checkpoint Inhibitors: Overview of Systematic Reviews

Salmaan Kanji, Sydney Morin, Kyla Agtarap, Debanjali Purkayastha, Pierre Thabet, Dominick Bosse, Xiang Wang, Carole Lunny, Brian Hutton

AdisInsight Report

Sutimlimab: First Approval

Sohita Dhillon

AdisInsight Report

Faricimab: First Approval

Matt Shirley

AdisInsight Report

Pacritinib: First Approval

Yvette N. Lamb

Correction

Correction to: Benefits and Harms of ‘Smart Drugs’ (Nootropics) in Healthy Individuals

Fabrizio Schifano, Valeria Catalani, Safia Sharif, Flavia Napoletano, John Martin Corkery, Davide Arillotta, Suzanne Fergus, Alessandro Vento, Amira Guirguis

Open Access Correction

Correction to: Daridorexant: First Approval

Anthony Markham

Aktuelle Ausgaben